<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03782688</url>
  </required_header>
  <id_info>
    <org_study_id>CVBA-CRI_0001</org_study_id>
    <nct_id>NCT03782688</nct_id>
  </id_info>
  <brief_title>Precise Percutaneous Coronary Intervention Plan (P3) Study</brief_title>
  <acronym>P3</acronym>
  <official_title>Prospective Evaluation of a Virtual Non-invasive Percutaneous Intervention Planner in Patients With Coronary Artery Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Onze Lieve Vrouw Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Onze Lieve Vrouw Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PRECISE PERCUTANEOUS CORONARY INTERVENTION (PCI) PLAN STUDY is an investigator-initiated,
      international and multicenter study of patients with an indication for PCI aiming at
      assessing the agreement and accuracy of the HeartFlow Planner with invasive fractional flow
      reserve (FFR) as a reference.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter study, including 120 patients at 5 centers in Europe and Asia. After identifying
      the presence of significant coronary stenosis by means of coronary angiography and invasive
      fractional flow reserve (FFR≤0.80) the patients will undergo the following procedures:
      Invasive FFR with intravenous adenosine (i.e. pre- and post-PCI). Optical coherence
      tomography-guided PCI (i.e. pre- and post-procedural imaging). PCI with newer generation
      drug-eluting stent.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">January 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Agreement on post-PCI fractional flow reserve between virtual treatment based on FFRct planner and measured invasive post-PCI fractional flow reserve.</measure>
    <time_frame>The primary endpoint will be assessed immediately after the procedure (PCI).</time_frame>
    <description>The agreement will be assessed by Cohen's Kappa coefficient</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Stable Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Single-arm cohort</arm_group_label>
    <description>Patients with significant coronary stenosis by invasive fractional flow reserve (FFR≤0.80)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FFRCT planner</intervention_name>
    <description>Non-invasive post-PCI fractional flow reserve prediction</description>
    <arm_group_label>Single-arm cohort</arm_group_label>
    <other_name>HeartFlow Planner</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Stable Coronary Artery Disease with Positive Fractional Flow Reserve and
        indication for percutaneous myocardial revascularization.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Coronary artery disease in a major epicardial vessel with an invasive fractional flow
             reserve (FFR) ≤0.80

          -  An indication to Percutaneous coronary intervention

        Exclusion Criteria:

        - Angiographic exclusion criteria

          1. Severely calcified lesion/vessel

          2. Bifurcation lesions.

          3. Ostial lesions.

          4. Left main disease.

          5. Severe vessel tortuosity.

        Clinical exclusion criteria

          1. Chronic obstructive pulmonary disease

          2. Contraindication to adenosine

          3. NYHA class III or IV, or last known left ventricular ejection fraction &lt;30%

          4. Uncontrolled or recurrent ventricular tachycardia

          5. Atrial fibrillation, flutter or arrhythmia

          6. History of recent stroke (≤90 days)

          7. History of acute coronary syndrome (≤90 days)

          8. Prior myocardial infarction

          9. History of ischemic stroke (&gt;90 days) with modified RANKIN score ≥ 2

         10. History of any hemorrhagic stroke

         11. Previous revascularization (PCI or Coronary artery bypass grafting)

         12. Active liver disease or hepatic dysfunction, defined as AST or ALT &gt; 3 times the ULN

         13. Severe renal dysfunction, defined as an eGFR &lt;30 mL/min/1.73 m2

         14. Body mass index&gt;35 kg/m2

         15. Nitrate intolerance

         16. Contra-indication to heart rate lowering drugs

             Imaging-related

         17. Insufficient coronary CT Angiography image quality.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Bernard De Bruyne, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>OLV-Aalst</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeroen CS Sonck, MD</last_name>
    <phone>+32477181454</phone>
    <email>jeroen.sonck@olvz-aalst.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carlos A Collet, MD</last_name>
    <phone>+3253724433</phone>
    <email>carlos.collet.bortone@olvz-aalst.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OLV-Aalst</name>
      <address>
        <city>Aalst</city>
        <state>Oost-Vlaanderen</state>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeroen CS Sonck, MD</last_name>
      <phone>003253724433</phone>
      <email>jeroen.sonck@olvz-aalst.be</email>
    </contact>
    <investigator>
      <last_name>Carlos A Collet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard De Bruyne, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 12, 2018</study_first_submitted>
  <study_first_submitted_qc>December 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2018</study_first_posted>
  <last_update_submitted>February 11, 2019</last_update_submitted>
  <last_update_submitted_qc>February 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Onze Lieve Vrouw Hospital</investigator_affiliation>
    <investigator_full_name>Jeroen Sonck</investigator_full_name>
    <investigator_title>Co-Director Cardiovascular Center OLV-Aalst</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided plan for data sharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

